The biotechnology and pharmaceutical company Abbvie, spelled AbbVie, was founded in 2013 as a spin-off from Abbott Laboratories and is traded on the NYSE stock exchange in the S&P 100 index under the symbol โABBVโ.
According to AbbVie's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 229. At the end of 2025 the company had a P/S ratio of 6.33.
Year | P/S ratio | Change |
---|---|---|
2025 | 6.33 | 13.37% |
2024 | 5.58 | 10.86% |
2023 | 5.04 | 2.32% |
2022 | 4.92 | 15.58% |
2021 | 4.26 | 3.14% |
2020 | 4.13 | 4.92% |
2019 | 3.94 | -5.43% |
2018 | 4.16 | -23.93% |
2017 | 5.47 | 37.85% |
2016 | 3.97 | -4.86% |
2015 | 4.17 | -20.04% |
2014 | 5.22 | 16.95% |
2013 | 4.46 | 51.93% |
2012 | 2.94 |
Company | P/S ratio | P/S ratio differencediff. | Country |
---|---|---|---|
![]() Pfizer PFE | 2.33 | -60.09% | ๐บ๐ธ USA |
![]() Bristol-Myers Squibb BMY | 2.01 | -65.61% | ๐บ๐ธ USA |
![]() Eli Lilly LLY | 14.2 | 143.81% | ๐บ๐ธ USA |
![]() Amgen AMGN | 4.68 | -19.91% | ๐บ๐ธ USA |
![]() Gilead Sciences GILD | 4.81 | -17.72% | ๐บ๐ธ USA |
![]() Biogen BIIB | 2.01 | -65.65% | ๐บ๐ธ USA |
![]() GlaxoSmithKline GSK | 1.93 | -67.01% | ๐ฌ๐ง UK |
![]() AstraZeneca AZN | 4.01 | -31.46% | ๐ฌ๐ง UK |
![]() Neurocrine Biosciences
NBIX | 5.28 | -9.62% | ๐บ๐ธ USA |